메뉴 건너뛰기
European Journal of Dermatology
Volumn 20, Issue 2, 2010, Pages 243-244
Improvement of psoriasis in a lung cancer patient treated with erlotinib
Author keywords

[No Author keywords available]
Indexed keywords

CISPLATIN; CORTICOSTEROID; DOCETAXEL; ERLOTINIB;
EID: 77950408289     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0882     Document Type: Letter
Times cited : (12)
References (6)
  • 1
    • 33745020186 scopus 로고    scopus 로고
    • Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. a role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
    • Wierzicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis ? Br J Dermatol 2006; 155: 213-214
    • (2006) Br J Dermatol , vol.155 , pp. 213-214
    • Wierzicka, E.1    Tourani, J.M.2    Guillet, G.3
  • 2
    • 54349117019 scopus 로고    scopus 로고
    • Cetuximab treatment in patient with metastatic colorectal cancer and psoriasis
    • Neyns B, Meert V, Vandenbroucke F. Cetuximab treatment in patient with metastatic colorectal cancer and psoriasis. Curr Oncol 2008; 15: 196-197
    • (2008) Curr Oncol , vol.15 , pp. 196-197
    • Neyns, B.1    Meert, V.2    Vandenbroucke, F.3
  • 3
    • 66449132603 scopus 로고    scopus 로고
    • Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients
    • de Noronha e Menezes NM. Lima R, Moreira A, Varela P, Barroso A, Baptista A, Parente B. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 2009; 19: 248-251
    • (2009) Eur J Dermatol , vol.19 , pp. 248-251
    • De Noronha E Menezes, N.M.1    Lima, R.2    Moreira, A.3    Varela, P.4    Barroso, A.5    Baptista, A.6    Parente, B.7
  • 4
    • 60549117569 scopus 로고    scopus 로고
    • Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy
    • Campbell TM, Brown Jr CW. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy. J Drugs Dermatol 2008; 7: 1161-1163
    • (2008) J Drugs Dermatol , vol.7 , pp. 1161-1163
    • Campbell, T.M.1    Brown Jr., C.W.2
  • 5
    • 0030627442 scopus 로고    scopus 로고
    • Different growth properties in response to epidermal growth factor and interleukin-6 of primary keratinocytes derived from normal and psoriatic lesional skin
    • Oyama N, Sekimata M, Nihei Y, Iwatsuki K, Homma Y, Kanelo F. Different growth properties in response to epidermal growth factor and interleukin-6 of primary keratinocytes derived from normal and psoriatic lesional skin. J Dermatolo Sci 1998; 16: 120-128
    • (1998) J Dermatolo Sci , vol.16 , pp. 120-128
    • Oyama, N.1    Sekimata, M.2    Nihei, Y.3    Iwatsuki, K.4    Homma, Y.5    Kanelo, F.6
  • 6
    • 0034131327 scopus 로고    scopus 로고
    • Inhibitors of tyrosine kinases in the treatment of psoriasis
    • Ben-Bassat H, Klein BY. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 2000; 6: 933-942
    • (2000) Curr Pharm des , vol.6 , pp. 933-942
    • Ben-Bassat, H.1    Klein, B.Y.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.